Juveena Hydrogel System
Rejoni, Inc. · Decision date Sep 28, 2026
What did the FDA approve?
The FDA approved the Juveena Hydrogel System from Rejoni, Inc. on September 28, 2026. The approval covers use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions.
The approval also includes the Rejoni Acorn Catheter, which is indicated to access the uterine cavity and deliver the Juveena Hydrogel solution into the uterine cavity. The device is classified as an absorbable adhesion barrier under product code MCN in obstetrics and gynecology. The database record does not include supplement type or supplement reason fields.
FDA approval order statement
Approval for Juveena Hydrogel System. The Juveena Hydrogel System is indicated for use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions.The Rejoni Acorn Catheter is indicated to access the uterine cavity and deliver the Juveena Hydrogel solution into the uterine cavity.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Obstetrics/Gynecology
- Decision date
- Sep 28, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250051
- Regulatory pathway
- Premarket approval application
- Applicant
- Rejoni, Inc.
- Product code
- MCN
- Decision code
- APPR
- Decision date
- Sep 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Barrier, absorbable, adhesion.
- Applicant
- Rejoni, Inc.
- Product code
- MCN
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250051 received
Application receipt date recorded by FDA.
P250051 · FDA decision
APPR
P250051/S001 · Related supplement
Juveena Hydrogel System
Timeline entries are records held by MedtechLedger for P250051. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250051
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juveena Hydrogel SystemP250051/S001 | Rejoni, Inc. | PMA supplement | Oct 28, 2026 | FDA |
Explore the linked device profile
Other records with product code MCN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
GYNECARE INTERCEED Absorbable Adhesion BarrierP880047/S072 | ETHICON, Inc. | PMA supplement | Nov 5, 2026 | FDA |
Womed LeafP240015/S003 | Womed Sas | PMA supplement | Oct 25, 2026 | FDA |
| Womed Sas | PMA approval | Sep 9, 2025 | FDA | |
| ETHICON, Inc. | PMA approval | Sep 15, 1989 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Rejoni, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 201 Burlington Rd., North Bldg., Second Floor, Bedford, MA, 01730
Sources and methodology
- Original FDA record: P250051
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

